Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhan, Shao-feng
ERASE, NCT06093191: Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis	Recruiting	4	364	RoW	Tobramycin Inhalant Product, Inhaled antibiotics, Ciprofloxacin 750 MG, Oral antibiotics, Oral ciprofloxacin placebo, Natural saline inhalation, Inhaled saline	Shanghai Pulmonary Hospital, Shanghai, China	Bronchiectasis Adult, Pseudomonas Aeruginosa Infection	10/25	12/25
NCT06760273: Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)	Recruiting	N/A	364	RoW	No Intervention: Observational Cohort	Shanghai Pulmonary Hospital, Shanghai, China	Bronchiectasis Adult	12/27	12/27
Ding, Yi-peng
ERASE, NCT06093191: Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis	Recruiting	4	364	RoW	Tobramycin Inhalant Product, Inhaled antibiotics, Ciprofloxacin 750 MG, Oral antibiotics, Oral ciprofloxacin placebo, Natural saline inhalation, Inhaled saline	Shanghai Pulmonary Hospital, Shanghai, China	Bronchiectasis Adult, Pseudomonas Aeruginosa Infection	10/25	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhan, Shao-feng
ERASE, NCT06093191: Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis	Recruiting	4	364	RoW	Tobramycin Inhalant Product, Inhaled antibiotics, Ciprofloxacin 750 MG, Oral antibiotics, Oral ciprofloxacin placebo, Natural saline inhalation, Inhaled saline	Shanghai Pulmonary Hospital, Shanghai, China	Bronchiectasis Adult, Pseudomonas Aeruginosa Infection	10/25	12/25
NCT06760273: Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)	Recruiting	N/A	364	RoW	No Intervention: Observational Cohort	Shanghai Pulmonary Hospital, Shanghai, China	Bronchiectasis Adult	12/27	12/27
Ding, Yi-peng
ERASE, NCT06093191: Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis	Recruiting	4	364	RoW	Tobramycin Inhalant Product, Inhaled antibiotics, Ciprofloxacin 750 MG, Oral antibiotics, Oral ciprofloxacin placebo, Natural saline inhalation, Inhaled saline	Shanghai Pulmonary Hospital, Shanghai, China	Bronchiectasis Adult, Pseudomonas Aeruginosa Infection	10/25	12/25